Sarepta Therapeutics (SRPT -7.6%) reversed an early gain to continue its descent lower today,...

|About: Sarepta Therapeutics, Inc. (SRPT)|By:, SA News Editor

Sarepta Therapeutics (SRPT -7.6%) reversed an early gain to continue its descent lower today, despite issuing a positive update from Phase IIb testing of its eteplirsen drug treatment for Duchenne muscular dystrophy. The company says data continues to show a statistically significant clinical benefit for patients after 62 weeks. Unfortunately, the stock has been in a steady decline since the company gave its presentation at the Deutsche Bank 2012 dbAccess BioFEST Conference in Boston on Tuesday.